Thomas Gad, Chief Business Officer at Y-mAbs Therapeutics, Inc. (YMAB), sold 150,000 shares at $6.83 ($1.0M) on 2023-12-14, disclosed to the SEC on 2023-12-15.
Seasonal sale ($1.0M) by Chief Business Officer — this insider has traded YMAB in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.58 | 50,000 | $329K | 32.9% |
| 2 | $6.83 | 50,000 | $342K | 34.1% |
| 3 | $6.61 | 50,000 | $331K | 33.0% |
| Total | $6.67 avg | 150,000 | $1.0M | 100% |
| Filing → |
| YMAB | SELL | 2024-06-11 | $841K | — | Filing → |
| YMAB | SELL | 2024-05-23 | $396K | — | Filing → |
| YMAB | SELL | 2024-03-07 | $128K | — | Filing → |